Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Assets: 2019-2025

Historic Assets for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $473.8 million.

  • Pharming Group N.V's Assets rose 11.34% to $473.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $473.8 million, marking a year-over-year increase of 11.34%. This contributed to the annual value of $400.0 million for FY2024, which is 13.58% down from last year.
  • Latest data reveals that Pharming Group N.V reported Assets of $473.8 million as of Q3 2025, which was up 6.17% from $446.3 million recorded in Q2 2025.
  • Over the past 5 years, Pharming Group N.V's Assets peaked at $473.8 million during Q3 2025, and registered a low of $382,323 during Q3 2022.
  • For the 3-year period, Pharming Group N.V's Assets averaged around $432.6 million, with its median value being $429.8 million (2023).
  • Its Assets has fluctuated over the past 5 years, first tumbled by 99.90% in 2022, then skyrocketed by 114,061.85% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Assets stood at $397.3 million in 2021, then rose by 7.17% to $425.8 million in 2022, then grew by 8.70% to $462.9 million in 2023, then fell by 13.58% to $400.0 million in 2024, then climbed by 11.34% to $473.8 million in 2025.
  • Its Assets was $473.8 million in Q3 2025, compared to $446.3 million in Q2 2025 and $403.2 million in Q1 2025.